Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 7, 2012, Pages 866-872

  Knuf, Markus ^a   Baine, Yaela ^b   Bianco, Véronique ^c   Boutriau, Dominique ^c   Miller, Jacqueline M ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Children; Immune memory; Meningococcal vaccine; Persistence; Tetanus toxoid; Toddlers

Indexed keywords

BACTERIAL VACCINE; DIPHTHERIA TOXOID CRM197; MENINGOCOCCUS VACCINE; NEW DRUG; TETRAVALENT MENINGOCOCCAL TETANUS TOXOID CONJUGATE VACCINE; TOXOID; UNCLASSIFIED DRUG;

ANTIBODY PERSISTENCE; ANTIBODY TITER; ARTICLE; BACTERICIDAL ACTIVITY; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; INFANT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TODDLER; VACCINATION;

ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; INFANT; MALE; MENINGOCOCCAL VACCINES; MICROBIAL VIABILITY; NEISSERIA MENINGITIDIS;

EID: 84864043364     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.20229     Document Type: Article

References (25)

1. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27(Suppl 2):B51-63; PMID:19477562; http://dx.doi.org/10. 1016/j.vaccine.2009.04.063
2. Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine 2006; 24:4692-700; PMID: 16621189; http://dx.doi.org/10.1016/j.vaccine.2006.03.034
3. Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 2006;19:142-64; PMID:16418528
4. Bröker M, Veitch K. Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine. Travel Med Infect Dis 2010;8:47-50; PMID:20188306; http://dx.doi.org/10.1016/j.tmaid.2009.12.001
5. Borrow R, Miller E. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned. Expert Rev Vaccines 2006; 5:851-7; PMID: 17184222; http://dx.doi.org/10.1586/14760584.5.6.851
6. Knuf M, Kieninger-Baum D, Habermehl P, Muttonen P, Maurer H, Vink P, et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 2010; 28:744-53; PMID:19887137; http://dx.doi.org/10.1016/j. vaccine.2009.10.064
7. Östergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009; 27:161-8; PMID:18834910; http://dx.doi.org/10.1016/j.vaccine.2008.08.075
8. Baxter R, Baine Y, Ensor K, Bianco V, Friedland LR, Miller JM. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr Infect Dis J 2011; 30:e41-8; PMID:21200360; http://dx.doi.org/10.1097/INF.0b013e3182054ab9
9. Bermal N, Huang L-M, Dubey AP, Jain H, Bavdekar A, Lin T-Y, et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccin 2011; 7:239-47; PMID:21343698; http://dx.doi.org/10.4161/hv.7.2.14068
10. Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, Tichmann-Schumann I, Maurer H, Maurer L, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine 2011; 29:4264-73; PMID:21420417; http://dx.doi.org/10.1016/j.vaccine.2011.03.009
11. Memish ZA, Dbaibo G, Montellano M, Verghese VP, Jain H, Dubey AP, et al. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J 2011; 30:e56-62; PMID:21278617; http://dx.doi.org/10.1097/ INF.0b013e31820e6e02
12. Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial. Vaccine 2011; 29:4274-84; PMID:21443965; http://dx.doi.org/10.1016/j.vaccine. 2011.03.043
13. Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, Morris R, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001; 183:160-3; PMID: 11078484; http://dx.doi.org/10.1086/317646
14. Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, et al The Multilaboratory Study Group. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 1997; 4:156-67; PMID:9067649
15. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003; 10:780-6; PMID:12965904
16. Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 2001; 69:1568-73; PMID:11179328; http://dx.doi.org/10.1128/IAI.69.3.1568-1573.2001
17. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 2005; 23:2222-7; PMID:15755600; http://dx.doi.org/10.1016/j.vaccine.2005.01.051
18. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010; 17:840-7; PMID: 20219881; http://dx.doi.org/10.1128/CVI.00529-09
19. Gill CJ, Baxter R, Anemona A, Ciavarro G, Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents. Hum Vaccin 2010; 6:881-7; PMID:21339701; http://dx.doi.org/10.4161/ hv.6.11.12849
20. Borrow R, Andrews N, Findlow H, Waight P, Southern J, Crowley-Luke A, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 2010; 17:154-9; PMID: 19906895; http://dx.doi.org/10.1128/CVI.00384-09
21. Trotter C, Borrow R, Andrews N, Miller E. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the prevaccination era. Vaccine 2003; 21:1094-8; PMID: 12559785; http://dx.doi.org/10.1016/S0264- 410X(02)00630-8
22. Trotter CL, Borrow R, Findlow J, Holland A, Frankland S, Andrews NJ, et al. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin Vaccine Immunol 2008; 15:1694-8; PMID:18827191; http://dx.doi.org/10.1128/CVI.00279-08
23. Trotter CL, Findlow H, Borrow R. Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009. Clin Vaccine Immunol 2012; 19:219-22; PMID:22190393; http://dx.doi.org/10.1128/CVI. 05515-11
24. Ceyhan M, Yildirim I, Balmer P, Riley C, Laher G, Andrews N, et al. Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005. Vaccine 2007; 25:7233-7; PMID:17707957; http://dx.doi.org/10.1016/j.vaccine.2007.07.019
25. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:853-61; PMID:21075057; http://dx.doi.org/10. 1016/S1473-3099(10)70251-6